Alzamend Neuro, Inc. income statement ALZN

Annual Quarterly

It recorded a net loss of $8.8 million. Diluted earnings per share were -$2.63.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2027 Jul 31, 2026	FY 2026 Apr 30, 2026	FY 2025 Apr 30, 2025	FY 2024 Apr 30, 2024	FY 2023 Apr 30, 2023	FY 2022 Apr 30, 2022	FY 2021 Apr 30, 2021
Research and development	3	4 +156.5%	1 -78.1%	6 -13.3%	7 +43.2%	5 +296.8%	1
Selling, general and administrative	6	5 +66.7%	3 -11.5%	3 -53.1%	7 +4.3%	7 +95.5%	4
Operating income	-9	-9 -95.0%	-4 +54.7%	-10 +33.2%	-15 -20.7%	-12 -148.8%	-5
Interest income	—	0	—	—	—	—	—
Interest expense	0	0 -63.3%	0 +78.5%	0 +31.2%	0 -83.4%	0 -67.3%	0
Other income (expense)	-0	-0 +69.3%	-0 -78.5%	-0 -31.2%	-0 +81.9%	-0 +55.1%	-0
Pretax income	—	-9 -94.3%	-5 +54.6%	-10 +33.1%	-15 -20.4%	-12 -145.0%	-5
Net income	-9	-9 -94.3%	-5 +54.6%	-10 +33.1%	-15 -20.4%	-12 -145.0%	-5
Basic EPS	-2.31	-2.63 +76.8%	-11.32 +91.4%	-132.33 -478.1%	-22.89	—	—
Diluted EPS	-2.31	-2.63 +76.8%	-11.32 +91.4%	-132.33 -478.1%	-22.89	—	—
Weighted average shares, basic	4	3 +640.3%	0 +507.8%	0 -88.6%	1 -99.3%	89	—
Weighted average shares, diluted	4	3 +640.3%	0 +507.8%	0 -88.6%	1	—	—
Other measures
Depreciation and amortization	0	0 +118.2%	0 +0.0%	0 +120.0%	0 +549.9%	0	—
EBITDA	-9	-9 -94.7%	-4 +55.0%	-10 +33.4%	-15 -20.6%	-12	—
Interest coverage	-1,480.55x	-1,324.50x	-249.42x	-983.83x	-1,930.98x	-264.80x	-34.77x

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ALZN (Nasdaq)
Fiscal year ends: April 30
Incorporated in: DE
Headquarters: Atlanta, GA
SEC filer status: , Emerging growth company
SEC CIK: 1677077

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.